Table 2.
Individual Participant Demographic and Clinical Characteristics Offset Against Change in overall HRQOL (T1–T3)
| Age Range | Years since Diagnosis | Sex | Original Diagnosis | Review Diagnosis | Treatment | Recurrence and Treatment | Epilepsy | Cognitive Functioning | Depression Above Cut-off | Fatigue Above Cut-off | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopsy | Resection | RT | Seizures (ever) | AEDs (at T3) | |||||||||||
| Improving HRQOL | |||||||||||||||
| 1 | 60–65 | 35 | M | Astrocytoma grade II | N/a | N | Y | N | N/a | Y | N | Stable across domains | Missing | Missing | |
| 2 | 40-45 | 28 | M | Astrocytoma grade II | N/a | Y | N | N | N/a | Y | Y | Improvement in EF, PF, WM, IP, AT | N | Y | |
| 3 | 35–40 | 31 | F | Astrocytoma grade II | N/a | N | Y | N | 1 Recurrence. Surgical resection | N | N | Improvement in PF; VM, WM, AT | N | Y | |
| 4 | 40–45 | 27 | F | Astrocytoma grade II | DNT | Y | N | Y | N/a | N | N | Improvement in PF, AT | N | Y | |
| 5 | 60–65 | 26 | M | Oligoastrocytoma grade II | N/a | N | Y | N | N/a | Y | Y | Stable across domains | Missing | N | |
| 6 | 40–45 | 19 | F | Astrocytoma grade II | Other glioma IDH wild type, NOS | N | Y | N | N/a | Y | Y | Improvement in PF, IP | Missing | Missing | |
| 7 | 60–65 | 26 | F | Astrocytoma grade II | N/a | N | Y | N | N/a | Y | N | Stable across domains | Y | Y | |
| 8 | 65–70 | 21 | M | Astrocytoma grade II | Other glioma IDH wild type, NOS | N | Y | Y | N/a | N | N | Improvement in EF, WM | N | Y | |
| 9 | 55–60 | 26 | M | Astrocytoma grade II | No evidence of tumour tissue | N | Y | N | N/a | Y | N | Stable across domains | Missing | Missing | |
| Stable HRQOL | |||||||||||||||
| 1 | 55–60 | 25 | F | Astrocytoma grade II | Diffuse astrocytoma IDH mutated | N | Y | Y | N/a | N | N | Improvement on PF | N | Y | |
| 2 | 40–45 | 25 | F | Astrocytoma grade II | N/a | ? | ? | N | N/a | Y | N | Improvement on VM | Y | N | |
| 3 | 65–70 | 23 | M | Astrocytoma grade II | N/a | N | Y | N | N/a | Missing | Missing | Missing | N | Y | |
| 4 | 65–70 | 31 | M | Astrocytoma grade II | N/a | N | Y | N | N/a | Y | Y | Stable across domains | N | Y | |
| 5 | 40–45 | 32 | F | Astrocytoma grade II | N/a | Y | N | Y | N/a | Y | N | Improvement on WM | Y | Y | |
| 6 | 45–50 | 26 | F | Astrocytoma grade II | N/a | N | Y | Y | 1 Recurrence. Radiotherapy | Y | N | Improvement on VM | N | N | |
| 7 | 35–40 | 23 | F | Astrocytoma grade II | N/a | N | Y | Y | N/a | N | N | Improvement on VM, IP | N | Y | |
| 8 | 70–75 | 22 | F | Oligodendroglioma grade II | Diffuse LGG, IDH mutated | N | Y | Y | 2 Recurrences. First time re-resection, second PCV chemotherapy. | N | N | Decline in IP | Missing | Missing | |
| Declining HRQOL | |||||||||||||||
| 1 | 40–45 | 29 | M | Astrocytoma grade II | N/a | Y | N | Y | N/a | N | N | Improvement in PF, WM | N | N | |
| 2 | 40–45 | 28 | F | Astrocytoma grade II | N/a | N | Y | N | N/a | N | N | Improvement in PF, VM | N | N | |
| 3 | 50–55 | 22 | F | Astrocytoma grade II | Diffuse astrocytoma IDH mutated | Y | N | N | 1 Recurrence. Surgery, radiotherapy and chemotherapy | Y | Y | Decline in IP | Y | Y | |
| 4 | 55–60 | 24 | M | Oligodendroglioma grade II | Other glioma IDH wild type, NOS | N | Y | N | N/a | Y | N | Improvement on WM | N | Y | |
| 5 | 60-65 | 33 | M | Astrocytoma grade II | N/a | N | Y | Y | 2 Recurrences. Two re-resections | Y | Y | Stable across domains | Missing | Missing | |
| 6 | 60-65 | 29 | M | Oligoastrocytoma grade II | N/a | ? | ? | Y | Missing | Y | Y | Decline in PF; improvement in VM | Y | Y | |
| 7 | 70-75 | 23 | F | Oligodendroglioma grade II | DNT | Y | N | N | N/a | Y | Y | Improvement on VM | N | Y | |
| Both declining and improving HRQOL | |||||||||||||||
| 1 | 40-45 | 26 | M | Astrocytoma grade II | N/a | N | Y | N | N/a | Y | N | Improvement in PF, WM | N | Y | |
| 2 | 50-55 | 23 | M | Astrocytoma grade II | Pilocytic astrocytoma or ganglioglioma | N | Y | N | N/a | Y | Y | Stable across domains | Y | N | |
| 3 | 40-45 | 28 | M | Astrocytoma grade II | N/a | N | Y | N | N/a | Y | N | Improvement in WM, IP, AT | N | N | |
| 4 | 40-45 | 27 | F | Astrocytoma grade II | N/a | Y | N | Y | N/a | Y | N | Decline in EF | Y | Y | |
| 5 | 45-50 | 26 | F | Astrocytoma grade II | N/a | N | Y | N | N/a | Y | N | Improvement in PF, IP, AT | Missing | Missing | |
| 6 | 35-40 | 29 | M | Astrocytoma grade II | Pilocytic astrocytoma | ? | ? | Y | 1 Recurrence. Surgery and radiotherapy | N | N | Improvement in PF; decline in AT | N | N |
AED, antiepileptic drug; AT, attention; EF, executive functioning; IP, information processing; LGG, low-grade glioma; NOS, not otherwise specified; PF, psychomotor functioning; VM, verbal memory; WM, working memory.